Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "ISA"

1128 News Found

India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat
News | October 31, 2025

India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat

The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million


Sanofi India appoints Deepak Arora as MD
People | October 28, 2025

Sanofi India appoints Deepak Arora as MD

Arora brings over 30 years of experience in the pharmaceutical and healthcare industry


CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors
News | October 27, 2025

CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors

The event will be attended by 35,000+ industry professionals


GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million
Biotech | October 27, 2025

GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million

Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile


Europe is putting vital medicines at risk by allowing ‘carbon heavy’ imports from the Far East: INEOS
News | October 25, 2025

Europe is putting vital medicines at risk by allowing ‘carbon heavy’ imports from the Far East: INEOS

INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East


Moderna discontinues congenital virus program after Phase 3 trial fails to meet primary endpoint
Clinical Trials | October 23, 2025

Moderna discontinues congenital virus program after Phase 3 trial fails to meet primary endpoint

Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target


KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer
Clinical Trials | October 22, 2025

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer

The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy


Roquette opens health and pharma solutions innovation center in Brazil
R&D | October 20, 2025

Roquette opens health and pharma solutions innovation center in Brazil

This new facility strengthens Latin America as a collaborative hub


Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million
News | October 17, 2025

Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million

Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio